Recent Updates
Recently added Catalysts
CORT Negative Sentiment Score: 20/100

Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT

Key Takeaway: Corcept Therapeutics is under scrutiny as a securities class action lawsuit has been initiated against the company. This lawsuit alleges that Corcept failed to disclose crucial information concerning the likelihood of FDA approval for its product candidate, relacorilant, during a specified Class Period. Following the FDA's issuance of a Complete Response Letter regarding the NDA, Corcept's stock price fell sharply by over 50%. Investors are reminded of a pending deadline to file lead plaintiff applications.

Market Sentiment Analysis

CONCERNS & RISKS

  • Corcept is facing a class action lawsuit due to alleged failure to disclose material information regarding FDA approval.
  • The company's share price dropped dramatically by 50.4% following an unfavorable FDA response on their product candidate.
  • Investors are reminded of the lead plaintiff deadline in a lawsuit against Corcept, indicating significant investor concern.
  • The lawsuit highlights potential risks associated with Corcept's management and their communications with investors.

Full Press Release Details

NEW ORLEANS, April 02, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) (“Corcept” or the “Company”), if they purchased or otherwise acquired the Company’s shares between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Corcept investors should visit us at https://claimsfiler.com/cases/nasdaq-cort-1/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Corcept and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The complaint alleges that, during the Class Period, the Company represented to investors that there was a high likelihood that one of its lead new product candidates, relacorilant, would receive approval from the U.S. Food and Drug Administration (“FDA”) after the Company’s New Drug Application (“NDA”) submission. However, on December 31, 2025, the Company disclosed that the FDA had issued a Complete Response Letter (“CRL”) regarding the NDA for relacorilant and that it had “concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.”
On this news, the price of Corcept’s shares plummeted by $35.40 per share, or 50.4%, from a closing price of $70.20 on December 30, 2025, to a closing price of $34.80 on December 31, 2025.
The case is Allegheny County Employees’ Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline to file a lead plaintiff application?

Investors must file lead plaintiff applications by April 21, 2026.

What is the class period for Corcept's lawsuit?

The class period for the lawsuit is from October 31, 2024, to December 30, 2025.

Why is Corcept facing a securities class action lawsuit?

Corcept is charged with failing to disclose material information about its product candidate.

What happened after the FDA's Complete Response Letter?

Corcept's shares dropped by 50.4%, from $70.20 to $34.80, on December 31, 2025.

Where can investors get more information about the lawsuit?

Investors can visit https://claimsfiler.com/cases/nasdaq-cort-1/ or call 844-367-9658.

Last updated: Apr 2, 2026